The new deep brain stimulation system for epilepsy seems best suited to patients whose seizures are hard to localize or restrict to just a couple brain regions. We share insights as one of the initial U.S. treating sites.
The new director of our DBS program looks ahead to emerging applications for DBS and advancements in related technology, from directional leads to closed-loop stimulation.
It took over six years, 20+ visits, participation in two clinical drug trials and more to convince this physician patient the time was right to try deep brain stimulation. We share caregiving lessons learned along the way.
The Director of our Center for Neurological Restoration explains this designation from the Parkinson’s Foundation, from the application process through the benefits for patient care and research.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The first-in-human study of deep brain stimulation (DBS) for stroke recovery also features the first combined use of transcranial magnetic stimulation with cerebellar DBS in humans. Here’s why that matters.
The team conducting the first-in-human clinical trial of deep brain stimulation for stroke recovery garnered $2.5M to continue parallel preclinical studies of the underlying mechanisms.
DBS-induced changes on magnetoencephalography reflect treatment effects and could serve as biomarkers for treatment efficacy.
A Cleveland Clinic research team confirmed in a randomized noninferiority trial that dexmedetomidine is an excellent sedative choice for patients with neurodegenerative disorders.
Here’s a status update from this historic trial, including a rundown of elements being investigated in addition to stroke survivors’ functional outcomes.
Functional improvements have not yet plateaued after four months of rehabilitative therapy plus deep brain stimulation (DBS) in the first patient to ever undergo DBS to restore motor function after stroke.